Pharmaprojects' Pharma R&D Annual Review 2018 assesses the industry trends by examining the pipeline by company, therapeutic area, disease, target and drug type, using data from Informa Pharma Intelligence’s Pharmaprojects, which has been tracking global drug development since 1980. This report focuses on research and development as it is now, how it is changing, fluctuating and being fine-tuned, and where it has been headed during 2017.
Ian Lloyd, Senior Director at Pharmaprojects and Data Integration, introduces the review:
"As a lifelong music lover and sometime DJ, I’ve chosen a musical theme for this year’s review. Drug development itself can be likened to a symphony, album, mixtape or DJ mix: it’s not enough to just have all the individual parts in place; for a really harmonious journey, each element needs to flow into the next in a way which is coordinated, balanced and mellifluous. The instruments need to be in tune and the constituent parts must be moving at sympathetic rhythms. This report will look at the hits and misses currently flooding the pharma airwaves. Is the industry’s top tune The Edge of Glory, or is it more a case of I Will Survive, or even worse, The End?"
Listen to the special Spotify playlist while you read, which includes a tongue-in-cheek collection of songs, specially curated as the perfect accompaniment to the Pharma R&D Annual Review 2018.